Observational studyBMC infectious diseases2025
Clinical, microbiological characteristics and outcomes of carbapenemase-producing enterobacterales bloodstream infections in a pediatric hospital in Brazil.
Observational study in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular characteristics, clinical risk factors, and outcomes of Klebsiella pneumoniae bloodstream infections in infants.BMC microbiology · 2026Article
- Genomic characterization ofFrontiers in microbiology · 2026Article
- Leveraging disease outbreak news to strengthen the global response to antimicrobial resistance: a call for action.Frontiers in public health · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundThe incidence of carbapenemase-producing Enterobacterales (CPE) infections has been rising globally and is associated with high morbidity and mortality. However, data on CPE bloodstream infections (BSIs) in pediatric populations remain limited.
methodsThis retrospective, single-center observational study included pediatric patients diagnosed with CPE BSI between August 2019 and December 2024 at a tertiary care hospital in southern Brazil. Demographic, clinical, and microbiological data were analyzed, along with outcomes including 30-day mortality, need for pediatric intensive care unit (PICU) admission, and length of hospital stay.
resultsA total of 41 episodes of CPE BSI were identified in 39 patients. Among them, 65.8% had a chronic illness, 41.5% were immunosuppressed, and 97.6% had a central venous catheter. Klebsiella pneumoniae was the most frequently isolated pathogen. Carbapenemase production included KPC (58.5%), NDM (36.6%), and co-production of both enzymes (4.9%). The 30-day mortality rate was 25.6%, rising to 47.0% in patients with sepsis (p = 0.011). Carbapenem use in the previous 3 months were significantly associated with lower mortality (p = 0.008).
conclusionCPE BSI in pediatric patients primarily affects those with underlying illnesses, immunosuppression, or prior healthcare exposure, and is associated with high mortality. These findings underscore the need for targeted prevention, early detection, and optimized management strategies in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.